NCT07266038 Effectiveness of Cross K-wire Vs Lateral Entry K-wire Fixation in Maintaining Reduction of Gartland Type 3 Supracondylar Fractures of Children
| NCT ID | NCT07266038 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Laiba Qamar |
| Condition | Gartland Type 3 Supracondylar Fracture |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-07-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study compares the efficacy of K wire when inserted in Cross V/s Lateral Direction in Supracondylar fractures of Gartland Type 3 in children. A comparative study.
Eligibility Criteria
Inclusion Criteria: All male and female patients of age 02-13 years with Gartland type 3 Supracondylar Fracture of Humerus less than 7 days old Exclusion Criteria: patients with open fractures patients with neurovascular injuries patients with medial column communition Fractures more than 7 Days old Ipsilateral fractures of radius/ulna or shaft of humerus pathological fractures which are associated with bone density changes
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07266038 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 13 Years, studying Gartland Type 3 Supracondylar Fracture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07266038 currently recruiting?
Yes, NCT07266038 is actively recruiting participants. Contact the research team at junikhan111@yahoo.com for enrollment information.
Where is the NCT07266038 trial being conducted?
This trial is being conducted at Bahawalpur, Pakistan.
Who is sponsoring the NCT07266038 clinical trial?
NCT07266038 is sponsored by Laiba Qamar. The trial plans to enroll 90 participants.